Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank

Authors

David E. Lanfear, Henry Ford HealthFollow
Jasmine A. Luzum, Henry Ford Health
Ruicong She, Henry Ford HealthFollow
Jia Li, Henry Ford HealthFollow
Hani N. Sabbah, Henry Ford HealthFollow
Nicole Zeld, Henry Ford HealthFollow
Bin Liu, Henry Ford HealthFollow
Edward L. Peterson, Henry Ford HealthFollow
Keoki L. Williams, Henry Ford HealthFollow

Recommended Citation

Lanfear DE, Luzum JA, She R, Li J, Sabbah HN, Zeld N, Liu B, Peterson E, and Keoki Williams L. Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank. Circ Genom Precis Med 2023; e003835.

Document Type

Article

Publication Date

4-1-2023

Publication Title

Circ Genom Precis Med

Medical Subject Headings

Humans; Biological Specimen Banks; Adrenergic beta-Antagonists/therapeutic use; Heart Failure/drug therapy/genetics; United Kingdom; adrenergic beta antagonists; genome wide association study; heart failure; precision medicine; survival

PubMed ID

36866666

ePublication

ePub ahead of print

Volume

16

Issue

2

First Page

e003835